Combination Chemotherapy, Bevacizumab, Radiation Therapy, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

/Home/Lung Cancer Healthcare and Treatment/Lung Cancer Clinical Trials/Non Small Cell Lung Cancer Clinical Trials

Combination Chemotherapy, Bevacizumab, Radiation Therapy, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), July 2008
Sponsors and Collaborators: UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00280150

Purpose
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high energy x-rays to kill tumor cells. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with bevacizumab, radiation therapy, and erlotinib may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of bevacizumab and erlotinib when given together with combination chemotherapy and radiation therapy and to see how well they work in treating patients with stage III non-small cell lung cancer.



Condition Intervention Phase
Lung Cancer
Biological: bevacizumab
Drug: carboplatin
Drug: erlotinib hydrochloride
Drug: paclitaxel
Radiation: 3-dimensional conformal radiation therapy
Phase I
Phase II




MedlinePlus related topics: Cancer Lung Cancer Radiation Therapy
Drug Information available for: Carboplatin Paclitaxel Erlotinib Erlotinib hydrochloride Bevacizumab
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control
Official Title: Phase I/II Trial of Induction Carboplatin/Paclitaxel With Bevacizumab Followed by Concurrent Thoracic Conformal Radiation Therapy With Carboplatin/Paclitaxel, Bevacizumab and Erlotinib in Stage IIIA/B Non-Small Cell Lung Cancer


Further study details as provided by National Cancer Institute (NCI):


Primary Outcome Measures:
Maximum tolerated dose of bevacizumab and erlotinib when given together with carboplatin, paclitaxel, and thoracic conformal radiotherapy (Phase I [closed to accrual as of 1/3/2008]) [ Designated as safety issue: Yes ]

Safety and toxicity profile of combining both bevacizumab and erlotinib hydrochloride with carboplatin, paclitaxel, and thoracic conformal radiotherapy (Phase I [closed to accrual as of 1/3/2008]) [ Designated as safety issue: Yes ]



Secondary Outcome Measures:
Progression-free survival (Phase II) [ Designated as safety issue: No ]

Overall toxicity profile (Phase II) [ Designated as safety issue: Yes ]

Response rate to induction therapy (Phase I [closed to accrual as of 1/3/2008] and II) [ Designated as safety issue: No ]

Toxicity profile of induction therapy (Phase I [closed to accrual as of 1/3/2008] and II) [ Designated as safety issue: Yes ]

Overall response rate and survival profile (Phase I [closed to accrual as of 1/3/2008] and II) [ Designated as safety issue: No ]

Feasibility and tolerability of administering consolidation therapy after induction therapy and chemoradiotherapy (Phase I [closed to accrual as of 1/3/2008] and II) [ Designated as safety issue: Yes ]


Estimated Enrollment: 50
Study Start Date: January 2006

Arms Assigned Interventions
Cohort 1: Experimental
Patients undergo thoracic conformal radiotherapy (TCRT) on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47. Patients also receive carboplatin IV and paclitaxel IV on days 1, 8, 15, 22, 29, 36, and 43 and bevacizumab IV over 30-90 minutes on days 1, 15, 29, and 43. Biological: bevacizumab
Given IV
Drug: carboplatin
Given IV
Drug: paclitaxel
Given IV
Radiation: 3-dimensional conformal radiation therapy
Given 5 days a week for 7 weeks
Cohort 2: Experimental
Patients undergo TCRT and receive carboplatin, paclitaxel, and bevacizumab as in cohort 1. Patients also receive oral erlotinib hydrochloride on days 2-5, 9-12, 16-19, 23-26, 30-33, 37-40, and 44-47. Biological: bevacizumab
Given IV
Drug: carboplatin
Given IV
Drug: erlotinib hydrochloride
Given orally
Drug: paclitaxel
Given IV
Radiation: 3-dimensional conformal radiation therapy
Given 5 days a week for 7 weeks
Cohort 3: Experimental
Patients undergo TCRT and receive carboplatin, paclitaxel, and bevacizumab as in cohort 1. Patients also receive higher doses of oral erlotinib hydrochloride on days 2-5, 9-12, 16-19, 23-26, 30-33, 37-40, and 44-47. Biological: bevacizumab
Given IV
Drug: carboplatin
Given IV
Drug: erlotinib hydrochloride
Given orally
Drug: paclitaxel
Given IV
Radiation: 3-dimensional conformal radiation therapy
Given 5 days a week for 7 weeks


Show Detailed Description


Eligibility


Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria
DISEASE CHARACTERISTICS:

Diagnosis of non-small cell lung cancer

Stage IIIA or IIIB disease
No malignant pleural or pericardial effusions
No palpable supraclavicular adenopathy
Squamous cell histology allowed provided there is no hemoptysis and no central invasive lesions that abut or invade major blood vessels in the chest (with or without cavitation)
Considered suitable and appropriate for combined modality therapy and thoracic conformal radiotherapy, as determined by the treating medical and radiation oncologist
PATIENT CHARACTERISTICS:

ECOG performance status 0-1
Hemoglobin ≥ 9.0 mg/dL
Platelet count ≥ 100,000/mm³
ANC ≥ 1,500/mm³
FEV_1 ≥ 1 L
Creatinine ≤ 1.5 times upper limit of normal (ULN)
AST or ALT ≤ 2.5 times ULN
Bilirubin normal
PTT and INR normal
Urine protein:creatinine ratio < 1.0
Blood pressure &#8804; 150/100 mm Hg on 3 separate occasions
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No significant recent hemoptysis (> ½ teaspoon of bright red blood)
No unstable angina
No NYHA congestive heart failure &#8805; class II
No myocardial infarction or stroke within the past 6 months
No clinically significant peripheral vascular disease
No evidence of bleeding diathesis or coagulopathy
No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
No serious, non-healing wound, ulcer, or bone fracture
No thrombosis requiring therapeutic anticoagulation
No significant traumatic injury within the last 28 days
PRIOR CONCURRENT THERAPY:

Recovered from prior surgery
At least 4 weeks since prior and no concurrent participation in another experimental drug study
At least 4 weeks since prior and no concurrent major surgical procedure or open biopsy
At least 2 weeks since prior mediastinoscopy or mediastinotomy
At least 1 week since prior fine needle aspirations or core biopsies
No other concurrent antineoplastic or antitumor agents, including chemotherapy, radiotherapy, immunotherapy, or hormonal anticancer therapy
No other concurrent investigational agents
Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00280150


Locations
United States, North Carolina
Batte Cancer Center at Northeast Medical Center Recruiting
CONCORD, North Carolina, United States, 28025
Contact: Contact Person 704-783-1322
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Recruiting
Chapel Hill, North Carolina, United States, 27599-7295
Contact: Clinical Trials Office - Lineberger Comprehensive Cancer Cente 877-668-0683; 919-966-4432
Wake Forest University Comprehensive Cancer Center Recruiting
Winston-Salem, North Carolina, United States, 27157-1096
Contact: Clinical Trials Office - Wake Forest University Comprehensive 336-713-6771

Sponsors and Collaborators
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
Investigators
Principal Investigator: David Morris, MD UNC Lineberger Comprehensive Cancer Center
Investigator: Mark A. Socinski, MD UNC Lineberger Comprehensive Cancer Center

More Information


Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers: CDR0000550142, UNC-LCCC-0511
Study First Received: January 19, 2006
Last Updated: February 6, 2009
ClinicalTrials.gov Identifier: NCT00280150 [history]
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
stage IIIA non-small cell lung cancer
stage IIIB non-small cell lung cancer
recurrent non-small cell lung cancer
squamous cell lung cancer



Study placed in the following topic categories:
Thoracic Neoplasms
Erlotinib
Non-small cell lung cancer
Bevacizumab
Carboplatin
Recurrence
Carcinoma
Respiratory Tract Diseases
Lung Neoplasms
Paclitaxel
Lung Diseases
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial



Additional relevant MeSH terms:
Respiratory Tract Neoplasms
Neoplasms by Site
Neoplasms
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Growth Substances
Physiological Effects of Drugs
Mitosis Modulators
Enzyme Inhibitors
Antimitotic Agents
Protein Kinase Inhibitors
Angiogenesis Inhibitors
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators
Growth Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents, Phytogenic



ClinicalTrials.gov processed this record on February 10, 2009


Back to top of Main Content


U.S. National Library of Medicine, Contact Help Desk
U.S. National Institutes of Health, U.S. Department of Health & Human Services,
USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act